FOLR1 and ovarian carcinoma: The phase 1 trial (NCT01609556) enrolled 44 patients with FRα-positive epithelial ovarian cancer (EOC) and tested MIRV doses ranging from 0.15 to 7.0 mg/kg every three weeks or weekly.